Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHSE:688016's Debt-to-EBITDA is ranked better than 97.03% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs SHSE:688016: 0.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Shanghai MicroPort Endovascular MedTech (Group) Co Debt-to-EBITDA Related Terms
Shanghai MicroPort Endovascular MedTech (Group) Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai MicroPort Endovascular MedTech (Group) Co Debt-to-EBITDA Chart
Shanghai MicroPort Endovascular MedTech (Group) Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai MicroPort Endovascular MedTech (Group) Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) has a Debt-to-EBITDA of 0.02 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co. This is 67% below median its historical median of 0.06. Over the past decade, Shanghai MicroPort Endovascular MedTech (Group) Co's Debt-to-EBITDA has ranged from 0.01 to 0.12. According to the industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #14 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 3%.
Is Shanghai MicroPort Endovascular MedTech (Group) Co's Debt-to-EBITDA too high?
Shanghai MicroPort Endovascular MedTech (Group) Co's current Debt-to-EBITDA of 0.02 is 67% below median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.12. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 0.02 is 98.8% below this industry median. Based on the distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #14 out of 471 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai MicroPort Endovascular MedTech (Group) Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai MicroPort Endovascular MedTech (Group) Co's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #14 out of 471 companies for Debt-to-EBITDA. This places Shanghai MicroPort Endovascular MedTech (Group) Co in the top 3% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.63. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 0.02 is 98.8% below this benchmark. Historically, Shanghai MicroPort Endovascular MedTech (Group) Co's own Debt-to-EBITDA has ranged from 0.01 to 0.12 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 1.63, Shanghai MicroPort Endovascular MedTech (Group) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai MicroPort Endovascular MedTech (Group) Co's current Debt-to-EBITDA of 0.02 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai MicroPort Endovascular MedTech (Group) Co's current Debt-to-EBITDA is 0.02, which is 67% below median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai MicroPort Endovascular MedTech (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥117.41, compared to a current price of ¥87.08 — trading 25.8% below its estimated fair value. The current Debt-to-EBITDA is 0.02, which is 67% below median its 10-year median of 0.06 and 98.8% below the Medical Devices & Instruments industry median of 1.63. Shanghai MicroPort Endovascular MedTech (Group) Co's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016), the current Debt-to-EBITDA is 0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co stock appears to be undervalued.
The current stock price of ¥87.08 is trading 25.8% below its estimated GF Value™ of ¥117.41.
GuruFocus considers Shanghai MicroPort Endovascular MedTech (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:688016:
Debt-to-EBITDA: 0.02 (67% below median its 10-year median of 0.06)
GF Value™: ¥117.41 vs. price of ¥87.08 (25.8% below fair value)
Industry Position: 98.8% below the Medical Devices & Instruments median (#14 of 471)
No single metric tells the full story. See the SHSE:688016 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Microport Endovascular Medtech Co Ltd is engaged in the Research, development, production and sales of interventional medical devices for the aorta and peripheral blood vessels.
93GF Score
Get the complete analysis for SHSE:688016
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688016 has been successfully added to your 
